Officials say the Brazilian state of Bahia has signed an agreement to conduct Phase III clinical trials of Russia's Sputnik V vaccine against Covid 19, and plans to buy 50 million doses for the market in Brazil.
The Russian vaccine is being developed’ by
the Gamaleya Research Institute in Moscow and is being marketed by the Russian
Foreign Investment Fund (RDIF), which last month tested and developed the
vaccine with the Brazilian state of Parana. What was the agreement?
Russia will sell 50 million doses of its
COVID-19 vaccine to the Brazilian state of Bahia under the name Sputnik-V, the
RDIF said in a statement.
Governor Rui Costa said an agreement had
been reached’ this week to prosecute and that Bahia would receive an initial
500 doses as soon as Brazilian health regulator Anvisa approved the protocol
for testing.
The RDIF added that the first supply would
begin "with consideration of the outcome of post-registration cases"
after approval by Brazilian regulators in November.
Russia has listed Sputnik as the world's
first vaccine against coronavirus, although Phase III trials are still pending.
The Phase III trial is a large-scale one
involving thousands of people - in Russia, 40,000 - over a long period of time.
If the trials are expected’ to pass in
October, Bahia will market the Russian vaccine in Brazil through its
pharmaceutical research center, Bahiafarma, said Navy State Health Secretary
Fabio Vilas Bose Pinto.
Brazil is the world's third most difficult
country to be infected’ with the corona virus, with more than a million
confirmed cases.
The Institute for Technology, set up for
the state of Parana, said last week that a separate Phase II trial would also
be held’ on 10,000 volunteers in Brazil in 2021.
Paraná's Institute of Technology, known as
Tecpar, will use imported doses for testing, but will begin developing vaccines
for the Brazilian market in the second half of next year.
RDIF has already signed two deals to
export the vaccine. Kazakhstan is initially ready to buy more than 2 million
doses and could later increase the volume to 5 million doses.
It has also agreed to sell 32 million
doses to a Mexican private company, Landsteiner Scientific.
The RDIF said this week that it expects to
supply 100 million doses of the vaccine to Latin America, close to one-fifth of
what it expects to be able to produce annually through a global manufacturing
partnership.
India will produce 300 million doses of
the vaccine.
READ MORE
0 Comments